GSK Plans $1.2B US Investment During Trump Visit
GSK to Invest $1.2 Billion in U.S. Research and Manufacturing During Trump Visit
LONDON – Pharmaceutical giant GlaxoSmithKline (GSK) has announced major new investments in the United States during the first day of President Donald Trump’s state visit to Britain.
The company said the funds will strengthen its research, development, and production capabilities across the U.S. The plan includes a $1.2 billion biologics factory in Pennsylvania to focus on respiratory and cancer treatments, as well as new artificial intelligence projects at five U.S. manufacturing sites.
GSK, which already employs about 15,000 people in the U.S., said the expansion would create hundreds of high-skilled jobs.
“This week’s state visit brings together two countries that have led the world in science and healthcare innovation,” GSK chief executive Emma Walmsley said.
The announcement comes as Trump continues pushing industries to increase domestic production. Since his re-election, he has imposed tariffs aimed at reducing what he calls an “unfair” U.S. trade deficit.
Mutib Khalid is a skilled content writer and digital marketer with a knack for crafting compelling narratives and optimizing digital strategies. Excel in creating engaging content that drives results and enhances online presence. Passionate about blending creativity with data-driven approaches, Mutib Khalid helps brands connect with their audience and achieve their goals.
